Summary

Persistence Market Research has recently released a comprehensive report on the China lung cancer screening market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the China lung cancer screening market from 2025 to 2032.

Key Insights:

•Projected Market Value (2032F): USD 1,295.5 Million
•China Market Growth Rate (CAGR 2025 to 2032): 11.2%
•China Lung Cancer Screening Market Size (2025E): USD 616.2 Million

China Lung Cancer Screening Market – Report Scope:

Lung cancer screening involves the use of diagnostic tools and imaging technologies, primarily low-dose computed tomography (LDCT), to detect early-stage lung cancer in high-risk populations. These screenings are increasingly conducted across hospitals, diagnostic centers, and community health programs. The market’s growth is supported by rising awareness of early cancer detection, government-led initiatives for public health improvement, and the expanding infrastructure for diagnostic imaging in China. Enhanced screening protocols, combined with AI-integrated diagnostic platforms, are improving the accuracy and efficiency of lung cancer detection.

Market Growth Drivers:

The China lung cancer screening market is propelled by several key factors, including the high prevalence of lung cancer due to widespread smoking, air pollution, and industrial exposure. The growing emphasis on early diagnosis to improve survival rates is driving the adoption of routine screening, particularly among individuals aged 50 and older with a history of smoking. Government policies, such as the inclusion of LDCT screening in national healthcare programs and subsidies for early diagnosis, are significantly accelerating market growth. Additionally, technological advancements, including AI-enhanced image analysis and mobile screening units, are expanding access to lung cancer screening in rural and underserved regions.

Market Restraints:

Despite promising growth prospects, the lung cancer screening market in China faces notable challenges. These include disparities in healthcare access between urban and rural regions, limited awareness in certain demographics, and concerns over overdiagnosis or radiation exposure from repeated CT scans. Furthermore, the cost of advanced diagnostic equipment and the need for trained radiologists may limit widespread adoption in less developed provinces. Regulatory approvals for novel screening technologies also present a hurdle for market entry and expansion.

Market Opportunities:

The market presents substantial opportunities driven by the integration of AI and machine learning in diagnostic imaging, enabling faster and more accurate interpretation of scan results. The rise of personalized medicine and biomarker-based risk assessment further enhances the relevance of lung cancer screening. Expanding public-private partnerships, mobile diagnostic units, and the development of low-cost, high-efficiency screening systems are expected to penetrate underserved populations. Continued investment in awareness campaigns and early detection programs will also stimulate demand across various regions in China.

Key Questions Answered in the Report:

•What are the primary factors driving the growth of the lung cancer screening market in China?
•Which screening technologies and protocols are gaining traction across different healthcare settings?
•How are advancements in AI and imaging reshaping lung cancer screening in China?
•Who are the key players contributing to the China lung cancer screening market, and what strategies are they employing to maintain competitiveness?
•What are the emerging trends and future prospects in China’s lung cancer screening ecosystem?

Competitive Intelligence and Business Strategy:

These companies are investing in AI-powered CT systems, mobile screening units, and cloud-based diagnostics to enhance early detection capabilities. Partnerships with public health institutions and hospitals support broader deployment and training programs. Furthermore, companies are exploring opportunities for value-based care models and outcome-driven screening programs to align with national health goals.

Key Companies Profiled:

•Biodesix
•GE HealthCare
•DELFI Diagnostics, Inc.
•Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
•CANON MEDICAL SYSTEMS CORPORATION
•Siemens Healthineers AG
•Medtronic plc
•Koninklijke Philips N.V.
•Freenome Holdings, Inc.
•Shanghai United Imaging Healthcare Co., LTD.
•Others

China Lung Cancer Screening Market Research Segmentation:

The lung cancer screening market in China encompasses a range of technologies, risk groups, end-user institutions, and regional dynamics, addressing early detection and risk mitigation strategies.

By Cancer Type

•Non-small Cell Lung Cancer (NSCLC)
•Small Cell Lung Cancer (SCLC)

By Diagnosis

•Low Dose Spiral CT Scan
•Chest X-ray

By End-use

•Hospitals and Clinics
•Diagnostic Centers
•Others

By Province

•Anhui
•Guizhou
•Guangdong
•Shandong
•Jiangsu
•Others

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. China Lung Cancer Screening Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-economic Factors
2.3.1. China’s Healthcare Expenditure and GDP Growth Trends
2.3.2. Government Initiatives and National Screening Programs
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Value Chain Analysis
3.3. PESTLE Analysis
3.4. Porter’s Five Force Analysis
4. Price Trend Analysis 2019-2032
4.1. Key Highlights
4.2. Key Factors Impacting Diagnosis Costs
4.3. Pricing Analysis by Cancer Type
5. China Lung Cancer Screening Market Outlook
5.1. China Lung Cancer Screening Market Outlook: Cancer Type
5.1.1. Introduction / Key Findings
5.1.2. Historical Market Sales Area (US$ Mn) and Analysis, By Cancer Type, 2019-2024
5.1.3. Current Market Sales Area (US$ Mn) and Analysis and Forecast, By Cancer Type, 2025-2032
5.1.3.1. Non-small Cell Lung Cancer (NSCLC)
5.1.3.2. Small Cell Lung Cancer (SCLC)
5.2. Market Attractiveness Analysis: Cancer Type
5.3. China Lung Cancer Screening Market Outlook: Diagnosis
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Sales Area (US$ Mn) Analysis, By Diagnosis, 2019-2024
5.3.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Diagnosis, 2025-2032
5.3.3.1. Low Dose Spiral CT Scan
5.3.3.2. Chest X-ray
5.4. Market Attractiveness Analysis: Diagnosis
5.5. China Lung Cancer Screening Market Outlook: End Use
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Sales Area (US$ Mn) Analysis, By Sales Area, 2019-2024
5.5.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Sales Area, 2025-2032
5.5.3.1.
5.5.3.1.1. Hospitals and Clinics
5.5.3.1.2. Diagnostic Centers
5.5.3.1.3. Others
5.6. Market Attractiveness Analysis: End Use
5.7. Market Attractiveness Analysis: Province
6. China Lung Cancer Screening Market Outlook: Province
6.1. Key Highlights
6.2. Historical Market Sales Area (US$ Mn) Analysis, By Province, 2019-2024
6.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Province, 2025-2032
6.3.1. Anhui
6.3.2. Guizhou
6.3.3. Guangdong
6.3.4. Shandong
6.3.5. Jiangsu
6.3.6. Others
6.4. Market Attractiveness Analysis: By Province
7. Competition Landscape
7.1. Market Share Analysis, 2025
7.2. Market Structure
7.2.1. Competition Intensity Mapping
7.2.2. Competition Dashboard
7.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
7.3.1. Biodesix
7.3.1.1. Overview
7.3.1.2. Solution Portfolio
7.3.1.3. Key Financials
7.3.1.4. Market Developments
7.3.1.5. Market Strategy
7.3.2. GE HealthCare
7.3.3. DELFI Diagnostics, Inc.
7.3.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7.3.5. CANON MEDICAL SYSTEMS CORPORATION
7.3.6. Siemens Healthineers AG
7.3.7. Medtronic plc
7.3.8. Koninklijke Philips N.V.
7.3.9. Freenome Holdings, Inc.
7.3.10. Shanghai United Imaging Healthcare Co., LTD.
7.3.11. Others
8. Appendix
8.1. Research Methodology
8.2. Research Assumptions
8.3. Acronyms and Abbreviations